These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2683758)

  • 1. Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation.
    Carpenter CB; Kirkman RL; Shapiro ME; Milford EL; Tiney NL; Waldmann TA; Zimmerman CE; Ramos EL; Strom TB
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):54-7. PubMed ID: 2683758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.
    Soulillou JP; Cantarovich D; Le Mauff B; Giral M; Robillard N; Hourmant M; Hirn M; Jacques Y
    N Engl J Med; 1990 Apr; 322(17):1175-82. PubMed ID: 2157982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: results of a randomized study.
    Kriaa F; Hiesse C; Alard P; Lantz O; Noury J; Charpentier B; Bazin H
    Transplant Proc; 1993 Feb; 25(1 Pt 1):817-9. PubMed ID: 8438496
    [No Abstract]   [Full Text] [Related]  

  • 5. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
    Waid TH; Lucas BA; Amlot P; Janossy G; Yacoub M; Cammisuli S; Jezek D; Rhoades J; Brown S; Thompson JS
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
    Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
    Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of anti-IL-2-receptor monoclonal antibody BT 563 in treatment of acute interstitial renal rejection.
    Carl S; Wiesel M; Daniel V; Staehler G
    Transplant Proc; 1995 Feb; 27(1):854-5. PubMed ID: 7879205
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of the immunosuppressive effect of fractionated total lymphoid irradiation (TLI) vs conventional immunosuppression (CI) in renal cadaveric allotransplantation.
    Waer M; Vanrenterghem Y; Ang KK; Van der Schueren E; Michielsen P; Vandeputte M
    J Immunol; 1984 Feb; 132(2):1041-8. PubMed ID: 6228588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo anti-interleukin-2 receptor (anti-Tac) therapy is immunosuppressive, but not tolerogenic.
    Ramos EL; Leggat JE; Milford EL; Kirkman RL; Tilney NL; Strom TB; Shapiro ME; Waldmann TA; Carpenter CB
    Trans Assoc Am Physicians; 1989; 102():231-9. PubMed ID: 2534707
    [No Abstract]   [Full Text] [Related]  

  • 10. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
    Lietz K; John R; Beniaminovitz A; Burke EM; Suciu-Foca N; Mancini DM; Edwards NM; Itescu S
    Transplantation; 2003 Mar; 75(6):781-7. PubMed ID: 12660501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients.
    van Gelder T; Mulder AH; Balk AH; Mochtar B; Hesse CJ; Baan CC; Vaessen LM; Weimar W
    J Heart Lung Transplant; 1995; 14(2):346-50. PubMed ID: 7779855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The multichain interleukin-2 receptor: a target for immunotherapy of patients receiving allografts.
    Waldmann TA; Goldman CK
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):45-53. PubMed ID: 2683757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation.
    Baan CC; Balk AH; van Riemsdijk IC; Vantrimpont PJ; Maat AP; Niesters HG; Zondervan PE; van Gelder T; Weimar W
    Transplantation; 2003 May; 75(10):1704-10. PubMed ID: 12777860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial.
    van Gelder T; Zietse R; Yzermans JN; Rischen-Vos J; Vaessen LM; Weimar W
    Transplant Proc; 1996 Dec; 28(6):3221-2. PubMed ID: 8962247
    [No Abstract]   [Full Text] [Related]  

  • 15. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation.
    Kirkman RL; Shapiro ME; Carpenter CB; McKay DB; Milford EL; Ramos EL; Tilney NL; Waldmann TA; Zimmerman CE; Strom TB
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1066-7. PubMed ID: 1989150
    [No Abstract]   [Full Text] [Related]  

  • 16. [Salvage therapy with anti-IL-2 receptor antibodies in high-risk kidney transplant patients].
    Carl S; Wiesel M; Deiss JM; Daniel V; Opelz G; Staehler G
    J Urol (Paris); 1997; 103(1-2):7-9. PubMed ID: 9765770
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of a primate model of renal transplantation in the development of new monoclonal antibodies.
    Shapiro ME; Reed MH; Strom TB; Carpenter CB; Milford EL; Kirkman RL
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):58-60. PubMed ID: 2816938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring.
    Abouna GM; al-Abdullah IH; Kelly-Sullivan D; Kumar MS; Loose J; Phillips K; Yost S; Seirka D
    Transplantation; 1995 Jun; 59(11):1564-8. PubMed ID: 7778170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific immunosuppression of corneal allograft rejection by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice.
    Hori J; Isobe M; Yamagami S; Mizuochi T; Tsuru T
    Exp Eye Res; 1997 Jul; 65(1):89-98. PubMed ID: 9237869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA 031) directed toward the human alpha/beta-T cell receptor.
    Knight RJ; Kurrle R; McClain J; Racenberg J; Baghdahsarian V; Kerman R; Lewis R; van Buren CT; Kahan BD
    Transplantation; 1994 Jun; 57(11):1581-8. PubMed ID: 8009591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.